Trastuzumab emtansine
- Generic Name
- Trastuzumab emtansine
- Brand Names
- Kadcyla
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1018448-65-1
- Unique Ingredient Identifier
- SE2KH7T06F
- Background
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine deriva...
- Indication
Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
- Associated Conditions
- HER2-Positive Early Stage Breast Cancer, HER2-positive, Metastatic Breast Cancer
- Associated Therapies
- -
HER2 Molecular Imaging with 89Zr-trastuzumab PET/CT As a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients with Advanced HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 87
- Registration Number
- NCT06595563
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT06439693
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 74
- Registration Number
- NCT06348134
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 240
- Registration Number
- NCT06324357
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 268
- Registration Number
- NCT06316531
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 442
- Registration Number
- NCT06313086
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 58
- Registration Number
- NCT06299852
- Locations
- 🇷🇺
N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russian Federation
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT06265428
- Locations
- 🇨🇳
015, Bengbu, Anhui, China
🇨🇳029, Hefei, Anhui, China
🇨🇳001, Beijing, Beijing, China
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1200
- Registration Number
- NCT06126640
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 178
- Registration Number
- NCT05945927
- Locations
- 🇨🇳
Beijing Hospital; Internal Medicine-Oncology, Beijing, China
🇨🇳The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China
🇨🇳Jiangmen Central Hospital, Jiangmen, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.